We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Pediatric Hypertrophic Cardiomyopathy: The High-Risk Profile of Massive Left Ventricular Hypertrophy

MedXY Editorial Team•Apr 24, 2026•Cardiology
Hypertrophic Cardiomyopathyleft ventricular hypertrophypediatric cardiologysudden cardiac death

Background

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, affecting 1 in 500 individuals globally. In children, massive left ventricular hypertrophy (LVH), defined as a maximal left ventricular wall thickness (MLVWT) ≥30 mm or a z score ≥+20, is a recognized risk factor for sudden cardiac death (SCD). However, the natural history and long-term outcomes of massive LVH in pediatric HCM remain poorly characterized, creating gaps in risk stratification and management strategies.

Study Design

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Unveiling a Cryptic MYBPC3 Variant Amplifying Missplicing in Hypertrophic CardiomyopathyA deep-intronic MYBPC3 variant magnifies natural mRNA missplicing events, causing hypertrophic cardiomyopathy and explaining previously genotype-negative cases through an ancient founder effect and novel splice regulation.Sep 18, 2026Physiological Left Atrial Staging as a Predictor of New-Onset Atrial Fibrillation in Hypertrophic CardiomyopathyA novel left atrial (LA) staging system, integrating hemodynamic load and contractile function, predicts new-onset atrial fibrillation risk in hypertrophic cardiomyopathy and may guide tailored AF surveillance.Sep 15, 2026Evolving Impact of Implantable Cardioverter-Defibrillators on Mortality Post-Myocardial Infarction: Insights from the PROFID StudyThe PROFID study reveals a declining mortality benefit from primary prevention implantable cardioverter-defibrillators in post-myocardial infarction patients with reduced ejection fraction over recent decades, highlighting changing clinicalAug 29, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Global Insights on Implantable Cardioverter-Defibrillators in High-Risk Hypertrophic Cardiomyopathy: Efficacy and Outcomes
An international multicenter study shows ICDs effectively prevent sudden death in high-risk hypertrophic cardiomyopathy patients, demonstrating low mortality rates and significant lifesaving interventions over long-term follow-up.
Aug 29, 2026
Rigosertib: A Promising Therapeutic Agent for Reversing Hypertrophic Cardiomyopathy in Noonan SyndromeRigosertib demonstrates significant reversal of hypertrophic cardiomyopathy and other syndromic features in Noonan syndrome models, highlighting its potential as a targeted therapy for RASopathy-associated cardiac and developmental abnormalAug 19, 2026
AI-Enabled ECG as a New Surveillance Tool for Left Ventricular Dysfunction in Hypertrophic Cardiomyopathy on MavacamtenThis study explores the potential of an AI-powered ECG tool to monitor left ventricular systolic dysfunction in hypertrophic cardiomyopathy patients treated with mavacamten, offering a less burdensome alternative to frequent echocardiogramsAug 12, 2026